Management of triple negative breast cancer

Catherine Oakman, Giuseppe Viale, Angelo Di Leo

Research output: Contribution to journalArticle

Abstract

Triple negative breast cancer (TNBC) accounts for approximately 15% of breast cancer cases. TNBC is an immunohistochemically defined subtype, with significant diversity within the subtype. Generally TNBC occurs in younger women and is marked by high rates of relapse, visceral and CNS metastases, and early death. Current therapy fails to curtail the innate aggressive behaviour of TNBC in the majority of patients. The poor prognosis coupled with a lack of targeted use of therapies is reflected in the high mortality. In a minority of patients with highly chemosensitive disease, no robust clinical evidence exists to guide use of current cytotoxics. Critical to optimal future management are accurate identification of truly triple negative disease and adequately powered prospective TNBC trials to establish treatment efficacy and define predictive biomarkers.

Original languageEnglish
Pages (from-to)312-321
Number of pages10
JournalBreast
Volume19
Issue number5
DOIs
Publication statusPublished - Oct 2010

Fingerprint

Triple Negative Breast Neoplasms
Instinct
Biomarkers
Breast Neoplasms
Neoplasm Metastasis
Recurrence
Mortality
Therapeutics

Keywords

  • Breast cancer
  • Immunohistochemistry
  • Predictive biomarker
  • Treatment
  • Triple negative

ASJC Scopus subject areas

  • Surgery

Cite this

Management of triple negative breast cancer. / Oakman, Catherine; Viale, Giuseppe; Di Leo, Angelo.

In: Breast, Vol. 19, No. 5, 10.2010, p. 312-321.

Research output: Contribution to journalArticle

Oakman, Catherine ; Viale, Giuseppe ; Di Leo, Angelo. / Management of triple negative breast cancer. In: Breast. 2010 ; Vol. 19, No. 5. pp. 312-321.
@article{c3304a6727d44490a8be816db9de52a5,
title = "Management of triple negative breast cancer",
abstract = "Triple negative breast cancer (TNBC) accounts for approximately 15{\%} of breast cancer cases. TNBC is an immunohistochemically defined subtype, with significant diversity within the subtype. Generally TNBC occurs in younger women and is marked by high rates of relapse, visceral and CNS metastases, and early death. Current therapy fails to curtail the innate aggressive behaviour of TNBC in the majority of patients. The poor prognosis coupled with a lack of targeted use of therapies is reflected in the high mortality. In a minority of patients with highly chemosensitive disease, no robust clinical evidence exists to guide use of current cytotoxics. Critical to optimal future management are accurate identification of truly triple negative disease and adequately powered prospective TNBC trials to establish treatment efficacy and define predictive biomarkers.",
keywords = "Breast cancer, Immunohistochemistry, Predictive biomarker, Treatment, Triple negative",
author = "Catherine Oakman and Giuseppe Viale and {Di Leo}, Angelo",
year = "2010",
month = "10",
doi = "10.1016/j.breast.2010.03.026",
language = "English",
volume = "19",
pages = "312--321",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",
number = "5",

}

TY - JOUR

T1 - Management of triple negative breast cancer

AU - Oakman, Catherine

AU - Viale, Giuseppe

AU - Di Leo, Angelo

PY - 2010/10

Y1 - 2010/10

N2 - Triple negative breast cancer (TNBC) accounts for approximately 15% of breast cancer cases. TNBC is an immunohistochemically defined subtype, with significant diversity within the subtype. Generally TNBC occurs in younger women and is marked by high rates of relapse, visceral and CNS metastases, and early death. Current therapy fails to curtail the innate aggressive behaviour of TNBC in the majority of patients. The poor prognosis coupled with a lack of targeted use of therapies is reflected in the high mortality. In a minority of patients with highly chemosensitive disease, no robust clinical evidence exists to guide use of current cytotoxics. Critical to optimal future management are accurate identification of truly triple negative disease and adequately powered prospective TNBC trials to establish treatment efficacy and define predictive biomarkers.

AB - Triple negative breast cancer (TNBC) accounts for approximately 15% of breast cancer cases. TNBC is an immunohistochemically defined subtype, with significant diversity within the subtype. Generally TNBC occurs in younger women and is marked by high rates of relapse, visceral and CNS metastases, and early death. Current therapy fails to curtail the innate aggressive behaviour of TNBC in the majority of patients. The poor prognosis coupled with a lack of targeted use of therapies is reflected in the high mortality. In a minority of patients with highly chemosensitive disease, no robust clinical evidence exists to guide use of current cytotoxics. Critical to optimal future management are accurate identification of truly triple negative disease and adequately powered prospective TNBC trials to establish treatment efficacy and define predictive biomarkers.

KW - Breast cancer

KW - Immunohistochemistry

KW - Predictive biomarker

KW - Treatment

KW - Triple negative

UR - http://www.scopus.com/inward/record.url?scp=77955709404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955709404&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2010.03.026

DO - 10.1016/j.breast.2010.03.026

M3 - Article

C2 - 20382530

AN - SCOPUS:77955709404

VL - 19

SP - 312

EP - 321

JO - Breast

JF - Breast

SN - 0960-9776

IS - 5

ER -